Prevention of heart embolic complications in atrial fibrillation: Possibilities of using rivaroxaban

Abstract


The review analyzes the role of atrial fibrillation concurrent with stable manifestations of coronary heart disease when novel oral anticoagulants are used. It gives the results of comparison of the efficacy and safety of warfarin and rivaroxaban in such patients in the large controlled ROCKET-AF trial.

Full Text

Предупреждение кардиоэмболических осложнений при фибрилляции предсердий у больных с коронарной болезнью сердца: возможности использования ривароксабана. - Аннотация. В обзоре анализируется роль сочетания фибрилляции предсердий со стабильными проявлениями ишемической (коронарной) болезни сердца при использовании новых пероральных антикоагулянтов. Представлены результаты сравнения эффективности и безопасности варфарина и ривароксабана у подобных больных в рамках крупного контролируемого исследования ROCKET-AF.

About the authors

I S Iavelov

Email: yavelov@yahoo.com

References

  1. You J.J., Singer D.E., Howard P.A. et al. Antithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl): e531S-e575S.
  2. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
  3. focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012: doi: 10.1093/eurheartj/ehs2.
  4. Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis. Ann Intern Med 1999; 131: 492-501.
  5. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med 2007; 146: 857-867.
  6. Connolly S.J., Eikelboom J., Joyner C. et al., for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
  7. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: 1903-1912.
  8. Hohnloser S.H., Pajitnev D., Pogue J. et al., for the ACTIVE W Investigators. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. JACC 2007; 50; 2156-2161.
  9. Heidbuche H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
  10. Granger C.B., Alexander J.H., McMurray J.J. et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
  11. Connolly S.J., Connolly S.J., Ezekowitz M.D. et al., for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1351.
  12. Patel M.R., Mahaffey K.W., Garg J. et al., for the ROCKET-AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
  13. Nieuwlaat R., Capucci A., Camm A.J. et al., on behalf of the Euro Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC Member Countries The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434.
  14. Nabauer M., Gerth A., Limbourg T. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
  15. Kakkar A.K., Mueller I., Bassand J.-P. et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163: 13-19.
  16. Alberts1 M.J., Bhatt D.L., Mas J.-L. et al., for the REduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009; 30: 2318-2326.
  17. Явелов И.С. Антитромботические препараты в профилактике тромбоэмболических осложнений после острого коронарного синдрома. Атеротромбоз 2013; 1: 82-104.
  18. Lip G.Y. H., Huber K., Andreotti F. et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association [EHRA] and the European Association of Percutaneous Cardiovascular Interventions [EAPCI]. Thromb Haemost 2010; 103: 13-28.
  19. Dans A.L., Connolly S.J., Wallentin L. et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2013; 127: 634-640.
  20. Hohnloser S.H., Oldgren J., Yang S. et al. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation 2012; 125: 669-676.
  21. Mahaffey K.W., White H.D., Nessel C.C. et al., on behalf of the ROCKET AF Investigators. Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial. Presented at the Scientific Sessions AHA 2011, Orlando: abstract 13492. Доступно в Интернет по адресу http://www.abstractsonline.com/plan/ViewAbstract.aspx&mID=2654&sKey=90b94d15-4a30-4d57-
  22. Patel M.R., Hellkamp A.S., Lokhnygina Y. et al. Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). JACC 2013; 61: 651-658.
  23. Mega J.L., Braunwald E., Mohanavelu S. et al., on behalf of the ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009; 374: 29-38.
  24. Gibson C.M., Chakrabarti A.K., Mega J. et al., for the ATLAS ACS 2-TIMI 51 Investigators. Reduction of Stent Thrombosis in Patients with Acute Coronary Syndrome Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51. JACC 2013: doi: 10.1016/j.jacc.2013.03.041.

Statistics

Views

Abstract - 92

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2013 Iavelov I.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies